The Department of Defense offers the GWIRP Investigator-Initiated Research Award to support innovative research on Gulf War Illness (GWI). The grant focuses on improving GWI case definition and diagnosis, characterizing disease symptoms, and understanding the pathobiology. It encourages studies on biomarkers to distinguish healthy Veterans from those with GWI. Research on chronic effects of neurotoxic exposures and testing of GWI-targeted pharmacologic agents are of interest. Applicants are encouraged to utilize specific approaches for biomarkers research and should demonstrate the potential impact of their project on GWI. The closing date for applications is October 29, 2015.
Opportunity ID: 276600
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | W81XWH-15-GWIRP-IIRA |
| Funding Opportunity Title: | DoD Gulf War Illness Investigator-Initiated Research Award |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement Grant |
| Category of Funding Activity: | Science and Technology and other Research and Development |
| Category Explanation: | – |
| Expected Number of Awards: | 5 |
| Assistance Listings: | 12.420 — Military Medical Research and Development |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 2 |
| Posted Date: | May 14, 2015 |
| Last Updated Date: | Jul 08, 2015 |
| Original Closing Date for Applications: | Oct 29, 2015 |
| Current Closing Date for Applications: | Oct 29, 2015 |
| Archive Date: | Nov 28, 2015 |
| Estimated Total Program Funding: | $3,600,000 |
| Award Ceiling: | $0 |
| Award Floor: | $0 |
Eligibility
| Eligible Applicants: | Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled “Additional Information on Eligibility” |
| Additional Information on Eligibility: | – |
Additional Information
| Agency Name: | Dept. of the Army — USAMRAA |
| Description: | The GWIRP Investigator-Initiated Research Award mechanism was first offered in FY06. Since then, 208 Investigator-Initiated Research Award applications were received, and 57 were recommended for funding. New for FY15: The GWIRP Investigator-Initiated Research Award contains explicit prescriptive language (see below) to guide applicants proposing investigations of potential biomarkers of GWI. The Investigator-Initiated Research Award is designed to promote new ideas in GWI research and establish proof of principle for further development in future studies. Applications are not required to include preliminary data; however, preliminary data may be used to support the objectives of an application. These data are not required to have come from the GWI research field. Applications not supported by preliminary data should be based on sound scientific rationale and may reflect clinical observations or seek to evaluate discoveries made in relation to other chronic multisymptom illnesses for their application in GWI. Regardless of the approach, the focus should be clearly on Veterans with GWI. It is the responsibility of the Principal Investigator (PI) to clearly and explicitly articulate the project’s potential impact on GWI. The Investigator-Initiated Research Award supports research focusing on the complex of symptoms known as GWI, improving the case definition and diagnosis of GWI, characterizing disease symptoms, and better understanding the pathobiology. The purpose of the award is to encourage basic through clinical research aimed at identification of objective measures (e.g., biomarkers) to distinguish healthy Veterans from those with GWI, or improve understanding of the pathobiology underlying symptoms associated with GWI. Studies that characterize chronic effects of neurotoxic exposures at dosages comparable to that encountered in-theatre during the Gulf War are of interest. Studies using animal models should focus on long-term and latent effects of toxic exposures to closely represent the current status of GWI patients. All studies using animal models should use an established model unless there is a compelling scientific justification for the development or use of a new model. Development of new animal models is discouraged. The Investigator-Initiated Research Award can also be used for testing of GWI-targeted pharmacologic agents in absorption, distribution, metabolism, and excretion (ADME) studies, and toxicology testing, including Investigational New Drug (IND)-enabling pharmacology/ toxicology testing. Preclinical development of non-pharmacological interventions is also acceptable. Applications Proposing Biomarker Research: The search for biomarkers of GWI is of interest to the GWIRP; however, GWI is a chronic, multisymptom illness resulting from exposures that occurred more than two decades ago. Applicants seeking to investigate biomarkers of GWI are strongly encouraged to employ one or more of the following approaches, which take into account confounding factors of biomarker investigations when applied to GWI populations, patient samples, and/or data: • Use of pre-existing GWI patient samples (and matched control samples) that have been evaluated to ensure artifacts of sample treatment or storage are known and controlled for; • Investigation of markers that have been identified in peer-reviewed scientific literature as having potential for diagnostic testing (e.g., markers of neural inflammation, mitochondrial dysfunction, hormonal imbalance, and others related to GWI pathobiology); • Validation of markers for GW-specific exposures independent of later events unrelated to GW deployment; • Focus on the identification of markers in subgroups that share symptomatology or on groups with known exposures to specific agents; • Investigative strategies recognizing the distinction between biomarkers of agent exposures, biomarkers of specific effects of agent exposures, and biomarkers of GWI; • For markers related to exposure, a wide survey of available GW exposure data should be performed. Investigation involving derivation of markers from animal models does not address the intent of the biomarker focus area under this award. |
| Link to Additional Information: | – |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
CDMRP Help Desk
301-682-5507 Email:help@eBRAP.org |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
| Deadline for pre-applications has been extended. | Jul 08, 2015 | |
| Jul 08, 2015 |
DISPLAYING: Synopsis 2
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | W81XWH-15-GWIRP-IIRA |
| Funding Opportunity Title: | DoD Gulf War Illness Investigator-Initiated Research Award |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement Grant |
| Category of Funding Activity: | Science and Technology and other Research and Development |
| Category Explanation: | – |
| Expected Number of Awards: | 5 |
| Assistance Listings: | 12.420 — Military Medical Research and Development |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 2 |
| Posted Date: | May 14, 2015 |
| Last Updated Date: | Jul 08, 2015 |
| Original Closing Date for Applications: | Oct 29, 2015 |
| Current Closing Date for Applications: | Oct 29, 2015 |
| Archive Date: | Nov 28, 2015 |
| Estimated Total Program Funding: | $3,600,000 |
| Award Ceiling: | $0 |
| Award Floor: | $0 |
Eligibility
| Eligible Applicants: | Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled “Additional Information on Eligibility” |
| Additional Information on Eligibility: | – |
Additional Information
| Agency Name: | Dept. of the Army — USAMRAA |
| Description: | The GWIRP Investigator-Initiated Research Award mechanism was first offered in FY06. Since then, 208 Investigator-Initiated Research Award applications were received, and 57 were recommended for funding. New for FY15: The GWIRP Investigator-Initiated Research Award contains explicit prescriptive language (see below) to guide applicants proposing investigations of potential biomarkers of GWI. The Investigator-Initiated Research Award is designed to promote new ideas in GWI research and establish proof of principle for further development in future studies. Applications are not required to include preliminary data; however, preliminary data may be used to support the objectives of an application. These data are not required to have come from the GWI research field. Applications not supported by preliminary data should be based on sound scientific rationale and may reflect clinical observations or seek to evaluate discoveries made in relation to other chronic multisymptom illnesses for their application in GWI. Regardless of the approach, the focus should be clearly on Veterans with GWI. It is the responsibility of the Principal Investigator (PI) to clearly and explicitly articulate the project’s potential impact on GWI. The Investigator-Initiated Research Award supports research focusing on the complex of symptoms known as GWI, improving the case definition and diagnosis of GWI, characterizing disease symptoms, and better understanding the pathobiology. The purpose of the award is to encourage basic through clinical research aimed at identification of objective measures (e.g., biomarkers) to distinguish healthy Veterans from those with GWI, or improve understanding of the pathobiology underlying symptoms associated with GWI. Studies that characterize chronic effects of neurotoxic exposures at dosages comparable to that encountered in-theatre during the Gulf War are of interest. Studies using animal models should focus on long-term and latent effects of toxic exposures to closely represent the current status of GWI patients. All studies using animal models should use an established model unless there is a compelling scientific justification for the development or use of a new model. Development of new animal models is discouraged. The Investigator-Initiated Research Award can also be used for testing of GWI-targeted pharmacologic agents in absorption, distribution, metabolism, and excretion (ADME) studies, and toxicology testing, including Investigational New Drug (IND)-enabling pharmacology/ toxicology testing. Preclinical development of non-pharmacological interventions is also acceptable. Applications Proposing Biomarker Research: The search for biomarkers of GWI is of interest to the GWIRP; however, GWI is a chronic, multisymptom illness resulting from exposures that occurred more than two decades ago. Applicants seeking to investigate biomarkers of GWI are strongly encouraged to employ one or more of the following approaches, which take into account confounding factors of biomarker investigations when applied to GWI populations, patient samples, and/or data: • Use of pre-existing GWI patient samples (and matched control samples) that have been evaluated to ensure artifacts of sample treatment or storage are known and controlled for; • Investigation of markers that have been identified in peer-reviewed scientific literature as having potential for diagnostic testing (e.g., markers of neural inflammation, mitochondrial dysfunction, hormonal imbalance, and others related to GWI pathobiology); • Validation of markers for GW-specific exposures independent of later events unrelated to GW deployment; • Focus on the identification of markers in subgroups that share symptomatology or on groups with known exposures to specific agents; • Investigative strategies recognizing the distinction between biomarkers of agent exposures, biomarkers of specific effects of agent exposures, and biomarkers of GWI; • For markers related to exposure, a wide survey of available GW exposure data should be performed. Investigation involving derivation of markers from animal models does not address the intent of the biomarker focus area under this award. |
| Link to Additional Information: | – |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
CDMRP Help Desk
301-682-5507 Email:help@eBRAP.org |
DISPLAYING: Synopsis 1
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | W81XWH-15-GWIRP-IIRA |
| Funding Opportunity Title: | DoD Gulf War Illness Investigator-Initiated Research Award |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement Grant |
| Category of Funding Activity: | Science and Technology and other Research and Development |
| Category Explanation: | – |
| Expected Number of Awards: | 5 |
| Assistance Listings: | 12.420 — Military Medical Research and Development |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Jul 08, 2015 |
| Last Updated Date: | – |
| Original Closing Date for Applications: | – |
| Current Closing Date for Applications: | Oct 29, 2015 |
| Archive Date: | Nov 28, 2015 |
| Estimated Total Program Funding: | $3,600,000 |
| Award Ceiling: | $0 |
| Award Floor: | $0 |
Eligibility
| Eligible Applicants: | Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled “Additional Information on Eligibility” |
| Additional Information on Eligibility: | – |
Additional Information
| Agency Name: | Dept. of the Army — USAMRAA |
| Description: | The GWIRP Investigator-Initiated Research Award mechanism was first offered in FY06. Since then, 208 Investigator-Initiated Research Award applications were received, and 57 were recommended for funding. New for FY15: The GWIRP Investigator-Initiated Research Award contains explicit prescriptive language (see below) to guide applicants proposing investigations of potential biomarkers of GWI. The Investigator-Initiated Research Award is designed to promote new ideas in GWI research and establish proof of principle for further development in future studies. Applications are not required to include preliminary data; however, preliminary data may be used to support the objectives of an application. These data are not required to have come from the GWI research field. Applications not supported by preliminary data should be based on sound scientific rationale and may reflect clinical observations or seek to evaluate discoveries made in relation to other chronic multisymptom illnesses for their application in GWI. Regardless of the approach, the focus should be clearly on Veterans with GWI. It is the responsibility of the Principal Investigator (PI) to clearly and explicitly articulate the project’s potential impact on GWI. The Investigator-Initiated Research Award supports research focusing on the complex of symptoms known as GWI, improving the case definition and diagnosis of GWI, characterizing disease symptoms, and better understanding the pathobiology. The purpose of the award is to encourage basic through clinical research aimed at identification of objective measures (e.g., biomarkers) to distinguish healthy Veterans from those with GWI, or improve understanding of the pathobiology underlying symptoms associated with GWI. Studies that characterize chronic effects of neurotoxic exposures at dosages comparable to that encountered in-theatre during the Gulf War are of interest. Studies using animal models should focus on long-term and latent effects of toxic exposures to closely represent the current status of GWI patients. All studies using animal models should use an established model unless there is a compelling scientific justification for the development or use of a new model. Development of new animal models is discouraged. The Investigator-Initiated Research Award can also be used for testing of GWI-targeted pharmacologic agents in absorption, distribution, metabolism, and excretion (ADME) studies, and toxicology testing, including Investigational New Drug (IND)-enabling pharmacology/ toxicology testing. Preclinical development of non-pharmacological interventions is also acceptable. Applications Proposing Biomarker Research: The search for biomarkers of GWI is of interest to the GWIRP; however, GWI is a chronic, multisymptom illness resulting from exposures that occurred more than two decades ago. Applicants seeking to investigate biomarkers of GWI are strongly encouraged to employ one or more of the following approaches, which take into account confounding factors of biomarker investigations when applied to GWI populations, patient samples, and/or data: • Use of pre-existing GWI patient samples (and matched control samples) that have been evaluated to ensure artifacts of sample treatment or storage are known and controlled for; • Investigation of markers that have been identified in peer-reviewed scientific literature as having potential for diagnostic testing (e.g., markers of neural inflammation, mitochondrial dysfunction, hormonal imbalance, and others related to GWI pathobiology); • Validation of markers for GW-specific exposures independent of later events unrelated to GW deployment; • Focus on the identification of markers in subgroups that share symptomatology or on groups with known exposures to specific agents; • Investigative strategies recognizing the distinction between biomarkers of agent exposures, biomarkers of specific effects of agent exposures, and biomarkers of GWI; • For markers related to exposure, a wide survey of available GW exposure data should be performed. Investigation involving derivation of markers from animal models does not address the intent of the biomarker focus area under this award. |
| Link to Additional Information: | – |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
CDMRP Help Desk
301-682-5507 Email:help@eBRAP.org |
Related Documents
Folder 276600 Full Announcement-1 -> gwirp_fy15_iira pa2_gg.pdf
Packages
| Agency Contact Information: | CDMRP Help Desk 301-682-5507 Email: help@eBRAP.org |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| 12.420 | PKG00216916 | May 14, 2015 | Oct 29, 2015 | View |
Package 1
Mandatory forms
276600 RR_SF424_2_0-2.0.pdf
276600 RR_Budget_1_3-1.3.pdf
276600 RR_KeyPersonExpanded_2_0-2.0.pdf
276600 PerformanceSite_2_0-2.0.pdf
Optional forms
276600 RR_SubawardBudget30_1_3-1.3.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
